INTERIM REPORT

Q1 2022

THE POWER
OF PRECISION.
FOR EVERY
ONCOLOGIST.
TODAY.

2curex

HIGHLIGHTS AND KEY FIGURES

EXECUTING ON OUR PLANS

This year we have set three goals that represent the progress in our go-to-market plan: introducing IndiTreat® in 30 hospitals across Europe, being present in 20 countries and launching 1 additional IndiTreat® test to complete our portfolio in metastatic colorectal cancer.

With the full focus and effort of our teams, we have made very good progress in the first quarter of 2022. We recruited 8 hospitals for the IGNITE program and are in advanced conversations with several more, we launched IndiTreat® Explore to identify drugs that could be used "off label" in third line mCRC patients, and we added 3 new countries – Poland, Czech and Slovakia – to our territories, reaching a total of 14 at the end of Q1.

We are confident that we are on track to achieve our goals for 2022 despite the turbulent economic and political situation in Europe at the moment.

FINANCIAL HIGHLIGHTS

The financial development is in line with our plans and expectations, and with a cash position of SEK 63.3 million at the end of Q1 2022, our capital resources can support the current activities and growth plans.

(KSEK)	**Q1 2022** *1/1-31/3*	**Q1 2021** *1/1-31/3*	**2021** *1/1-31/12*
Net sales	0	0	0
Other operating income	434	3 850	7 391
Profit before tax	-7 897	-2 222	-21 679
Earnings per share (SEK)*	-0,45	-0,12	-1,10
Equity ratio**	96%	94%	94%
Cash and bank	63 348	53 991	72 942
Average number of shares	17 513 876	14 856 600	16 418 767
No. of shares by the end of the period	17 602 916	14 856 600	17 475 716

**Earnings per share: Profit for the period divided by the average number of shares.*

***Equity ratio: Shareholder's equity divided by total capital.*

HIGHLIGHTS IN Q1

2022

JAN

- New Institutional shareholder
- New Distributor for IndiTreat® in Czech Republic and Slovakia through Promedica, and in Poland through Perlan Technologies

FEB

- Announces a reorganization to an even stronger distributor focus
- Publising Q4 2021 and a virtual live session presenting the Q4 2021 report

MAR

- 2cureX launches IndiTreat® mCRC Explore and completes portfolio rollout plan for 2022
- Mangold Fondkommission AB published an updated Analyst Report on 2cureX

APR

- Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program
- Manuel Fernández joins 2cureX as Director of Quality Assurance and Regulatory Affairs.
- Notice of annual general meeting of 2cureX AB

MAY

- 2cureX publishes the annual report for the fiscal year 2021
- Redeye research interview with 2cureX CEO, Fernando Andreu
- 2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company's share
- 2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine
- IGNITE update: Eight hospitals have been enrolled in the program
- Presenting Dr. Michael Schaefer in regards to the nomination to the Board of Directors
- Three IndiTreat® posters have been accepted at ESMO-GI 2022

FOR MORE INFORMATION PLEASE CONTACT:

Fernando Andreu, CEO
Mail: fa@2curex.com
Mobile: +45 2279 5399

Ole Thastrup, CSO
Mail: ot@2curex.com
Mobile: +45 2211 5399

www.2curex.com

FOCUSED ON OUR MARKET-ORIENTED GOALS

Last year represented a turning point for 2cureX, as we developed new skills and assets and became more market oriented, in line with the degree of maturity the company had reached and our vision of making Drug Sensitivity Testing part of the routine clinical practice in oncology.

This increased emphasis on the market is reflected in the three goals that we have declared for this year. The efforts of the whole organization are fully focused on achieving these goals, and we have seen very good progress in all of them during the first quarter of 2022.

OUR 2022, MARKET-ORIENTED GOALS

First, we want to introduce the IndiTreat® test in innovative hospitals, that can become reference for others and create the critical mass of real-life evidence required to include the test in guidelines. This is the aim of our IGNITE program, and we set for ourselves the challenging goal of having 30 hospitals using the test by the end of the year.

The second goal is related to our geographic coverage. The more countries we are in, the faster we can reach this critical mass of users. The model we have chosen, through local partnerships with distributors, allows us to expand with very limited investment in infrastructures. We ended 2021 with presence in 11 countries and aim at being in 20 countries by the end of 2022.

Finally, we set the goal of having one more product launched, to complete our offering in metastatic colorectal cancer and increase the value proposition for oncologists and their patients. After having launched in 2021 our IndiTreat® mCRC Start and mCRC Extend, both assessing sensitivity to drugs included in guidelines, we wanted to offer alternative options for third-line patients by looking at drugs that are approved for other indications but can be effective in colorectal cancer as well. Hence IndiTreat® mCRC Explore.

STRONG INTEREST OF ONCOLOGISTS IN THE IGNITE PROGRAM

The IGNITE – Inducing Growth through a Network of IndiTreat Evaluations – program will accelerate the uptake of IndiTreat® in hospitals by offering them a limited number of patients tested with IndiTreat® at no cost, in exchange for sharing their results at conferences and scientific events.

Hospitals and distributors are still disrupted by the aftermath of the COVID restrictions, having to catch up with a backlog of projects and activities that were put on hold in the last two years. Despite this unfavorable circumstance, IndiTreat® is creating strong interest from the oncologists and we expect an acceleration in number of hospitals as the commercial activities ramp up. Beside the 8 hospitals already enrolled in the IGNITE program, we are in advanced discussions with additional 8 hospitals and confident that the goal of 30 hospitals will be fulfilled at the end of the year.

CONSOLIDATING OUR DISTRIBUTOR NETWORK

With regards to building up the network of commercial partners, our second goal, we added 3 new countries – Poland, Czech and Slovakia – in Q1 2022. After signing up these countries we paused the expansion because the new distributors needed to be onboarded and trained, a process that takes time. Once this has been done, we have re-started conversations with potential partners in several countries and expect to sign several new contracts already in Q2. The goal of covering 20 countries by year end is within reach.

PRODUCT PORTFOLIO COMPLETED FOR 2022

In March we launched IndiTreat® mCRC Explore, thus achieving the goal we had set for this year in terms of portfolio expansion. Having this product in the market as soon as possible was very important, not only for commercial purposes but for regulatory reasons. The new IVD Regulation (IVD-R) comes into force on May 26th, therefore all products launched after that date will need to follow the new process – much longer and complex – to be CE-marked. But products already in the market before that date, CE-marked under the current process (IVD-D), can continue to be commercialized for an extended period – four additional years in the case of the IndiTreat® tests – It was therefore important to launch the product before 26th of May to avoid delays due to the shortage of Notified Bodies to certify products under the new IVD-R.

With IndiTreat® mCRC Explore we have completed the offering for metastatic colorectal cancer. The next product in the pipeline will still address colorectal cancer but in earlier stages.

ON TRACK FOR A SUCCESSFUL YEAR

We have had a good start in 2022. The reception we got for our IndiTreat® tests is encouraging, and we have a growing number of salespeople promoting them across Europe, so we expect the enrollment of hospitals will speed up in the coming months. At the same time, there is a growing awareness in the market of the limitations of current approaches to personalized oncology, and the openness of key stakeholders in the hospitals for discussions has never been better. The complexity of internal hospital procedures, now further stressed by the post-covid catch up, and the uncertainty generated by the situation in Ukraine, especially in neighboring countries, are certainly factors that we must live with and manage on a daily basis. Nevertheless, we are, with the strong commitment and focus of our team and our commercial partners, on track for another successful year.

Fernando Andreu, *CEO*
May 24, 2022

2CUREX IN BRIEF

The key product of 2cureX is the IndiTreat® test portfolio, which allows the physician to identify the most efficient medical treatment for a particular cancer patient.

For more details see 2cureX's website at
www.2curex.com

TECHNICAL EXPANSIONS – NOW AND IN THE FUTURE

EXPANDING OUR INDITREAT® TESTING CAPACITY

To address the planned demand of IndiTreat® tests as we are rolling out our metastatic colorectal cancer portfolio throughout Europe, we have initiated the works to setup a new testing lab in Copenhagen. This facility, located in the same building as our current R&D lab, will be fully dedicated to conducting *In Vitro Diagnostic* (IVD) testing on patient samples. The laboratory will be organized and run according to the latest regulatory requirements, and seek the relevant accreditations. It is expected to be operational in the fourth quarter of this year.

INDITREAT® AUTOMATION

In 2020 2cureX established a collaboration with Hahn-Schickard micro-engineering center in Freiburg to automate critical parts of the IndiTreat® process. Hahn-Schickard has a proven track record in developing applications for bio-printing single cells and microtumors in the field of personalized diagnostics. The collaboration, which is financially supported by the German Ministry for Education and Research (BMBF), has been very productive so far. A first prototype was tested in 2cureX facilities last year, and an improved version including the proposed modifications is ready to be evaluated in Q2 this year.

This project is of strategic importance for the expansion plans of 2cureX. The implementation of such instrument will not only increase the productivity in our labs and improve the performance of the technology, but most importantly, will allow the implementation of IndiTreat® in multiple labs by standardizing the process and avoiding inter-laboratory variability. This opens the door to new, attractive markets such as North America, Middle East or South East Asia where the IndiTreat® technology could be deployed in labs acting as "Regional testing hubs" with the same standard of quality and consistent results as we actually have in our Copenhagen lab.

Hahn Schickard

IVD-R IS HERE – WHAT DOES IT MEAN FOR 2CUREX?

We welcome the new regulation and think that having more stringent product development requirements and supervision by authorities benefits the IVD industry credibility.

In 2021 and beginning of 2022 we have worked in implementing an ISO 13485 certified QMS that is compliant with the new requirements. Having three IndiTreat® tests in the market before May 26th that we can continue to commercialize without changes for the next four years is a good basis to continue our commercial rollout.

Most importantly, the new regulation means that any competitive product that is launched after May 26th will be subject to the new, longer, and more complex CE marking process. All in all, the new framework distinctly separates research companies from IVD companies, clarifying the competitive environment, and positioning 2cureX with a very selected group of other companies in the position to lead the implementation of drug sensitivity testing in clinical routine.

THE IVD-REGULATION (IVD-R)

The Regulation (EU) 2017/746, more commonly known as the IVD-R, establishes a new regulatory framework in Europe for *In Vitro Diagnostic* (IVD) medical devices. These include instruments, reagents, consumables, calibrators and controls, software and any other product involved in providing a result related to the patient's state of health or disease, congenital abnormalities or compatibility among donors and recipients of blood or organs.

The European legislators passed this new Regulation back in 2017 with the aim of setting higher safety and quality standards for IVD medical devices and increasing patient's health protection. The application date was set to May 26th, 2022.

THE NEW REGULATION COMPARED TO THE PREVIOUS DIRECTIVE 98/79/EC

Formally, it's a Regulation, which means it is legally binding in every member state and enters into force at the same time in all member states – vs. a Directive, which is a guidance on certain goals, that each member state must later transpose into national laws –.

In terms of content, there are three main differences:

- CE Marking: Most IVDs were until now "self-declared", meaning they could display the CE Mark based on the manufacturer's own "Declaration of Conformity" with the Directive. Under IVD-R, most IVDs will require a qualified third party (Notified Body) assessment and certification for CE Marking, a process much longer and complex.

- Post Market Surveillance (PMS): IVD manufacturers are expected to have a system to collect and evaluate relevant information from the products they have in the market, and to identify the need to take any action. Under IVD-R, Notified Bodies will strengthen the supervision of the manufacturer's PMS system.

- Unique Device Identification (UDI) and EUDAMED database: IVD manufacturers are required under IVD-R to assign a code, using a standard format, to all their products. All information about the coded device – certificates, clinical investigations, performance studies, vigilance, market surveillance, etc. – will be available for users and regulators in a European database, EUDAMED.



Some additional changes include the definition of the regulatory role of importers and distributors, and the requirement that companies formally assign the responsibility of regulatory compliance to a quality or regulatory manager.

IVD-R COMPLIANCE AT 2CUREX

While IVD-R comes into full force on May 26th this year, the legislators have provided an extended transition period (variable depending on product classes) due to the lack of capacity in Notified Bodies.

IndiTreat® tests already in the market prior to May 26th, 2022, and CE Marked under IVD-D can continue to be commercialized without any changes four additional years, until May 26th, 2026. Before that date, they will have to be re-certified by a Notified Body under IVD-R.

New IndiTreat® tests to be launched after May 26th, 2022, will have to undergo the new process with assessment and certification by a Notified Body, therefore we expect significant longer periods between the beginning of a development project and its final launch. Our product development processes, conducted under ISO 13485, are compliant with the requirements of IVD-R, including the definition of the PMS plan for our products.

Regarding the implementation of UDI in EUDAMED, Class C devices – IndiTreat® classification under IVD-R – have until May 26th, 2025, to be registered.

WELCOME TO MANUEL FERNANDEZ

Manuel joined the 2cureX team in April 2022, as Director of Quality Assurance and Regulatory Affairs. "I am thrilled to be part of this journey, helping bring 2cureX operations to the highest quality standards and guiding future IndiTreat® products and services smoothly through the regulatory system", Says Manuel.

Manuel Fernández, *Director of Quality Assurance and Regulatory Affairs*

2CUREX PARTICIPATES AT ESMO WORLD CONGRESS ON GASTRO-INTESTINAL CANCER

– 3,200 ONCOLOGY PROFESSIONALS IN ONE PLACE

The European Society of Medical Oncology (ESMO) is hosting the annual World Congress on Gastrointestinal Cancer in Barcelona, Spain, from June 29th to July 2nd.

This is the largest European gathering of healthcare professionals in the field of gastrointestinal (GI) cancer, with more than 3,200 attendees including medical oncologists, surgeons, pathologists, and radiologists.

GI cancer refers to the gastrointestinal tract organs. Most common are colorectal cancers – 2cureX current focus with IndiTreat® mCRC Start, Extend and Explore – followed by gastric (stomach), liver, esophageal and pancreatic.

For 2cureX, this is a unique opportunity to engage face to face with a large number of potential customers, present the benefits of using IndiTreat® to guide therapy decision-making, and discuss the IGNITE program. We expect to accelerate the recruitment of hospitals for the program as a consequence of our ESMO GI participation.

Beyond having a booth to present IndiTreat® and setting up meetings with customers, we will be present in the scientific area with three posters:

#546: In vitro drug screening of patient-derived 3D tumoroids replicates resistance to FOLFOX, FOLFIRI, and FOLFOXIRI in clinically resistant patients with metastatic colorectal cancer (together with University Hospital Vejle – Vejle, Denmark)

#212: Precision oncology without biomarkers: Assessing drug sensitivity in patient-derived tumoroids to guide mCRC 3rd line therapy

#668: In vitro drug screening of patient-specific tumoroids to predict chemotherapeutic treatment response in Pancreatic ductal adenocarcinoma: An interim analysis (together with University Clinic Eppendorf – Hamburg, Germany)

These posters highlight the benefits of the current IndiTreat® products (mCRC Start, mCRC Extend and mCRC Explore) as well as the advances in developing a new application for Pancreatic cancer and will support our discussions with potential customers.

This is an unprecedented event for 2cureX, since previous participations in large scale conferences were in virtual format due to COVID restrictions, a format that does not favor the introduction of new companies and technologies. We are looking forward to a successful congress.



DEVELOPMENT DURING THE FIRST QUARTER OF 2022, IN FIGURES

Numbers within parentheses refer to the corresponding period in the preceding year. For additional information about 2cureX's financial position and development, please refer to the Company's website (www.2cureX.com).

NET SALES AND OPERATING INCOME
Net sales for the first quarter of 2022 amounted to 0 KSEK (0 KSEK). Other operating income for the first quarter amounted to 434 KSEK (3 850 KSEK).

FINANCIAL DEVELOPMENT
The result for the first quarter of 2022 amounted to -7 897 KSEK (-1 835 KSEK). The result for the period has been impacted by the increasing efforts to build the market awareness of our IndiTreat® technology, and commercial efforts to market IndiTreat®.

LIQUIDITY
The Group's cash and cash equivalents amounted to 63 348 KESK (53 991 KSEK) as of March 31, 2022. Cash flow amounted to -9 710 KSEK (-4 995 KSEK). Cash flow from operating activities in the first quarter of 2022 amounted to -9 710 KSEK (-4 928 KSEK). The monthly average burn rate is approxima- tely 3.2 MSEK, which is in line with the expectations.

SOLIDITY
The Group's equity ratio as of March 31, 2022 amounted to 96 percent (94).

THE SHARE
There is one class of shares in 2cureX AB (publ). The Company's share is listed on Nasdaq First North Growth Market under the ticker "2CUREX". As of March 31, 2022, the number of shares amounted to 17 602 916 (14 856 600). The average number of shares during the first quarter of 2022 amounted to 17 513 876 (14 856 600).

WARRANT PROGRAM FOR EMPLOYEES AND BOARD MEMBERS
The extra general meeting on November 5, 2020 resolved to establish a warrant program for three new board members. The warrant program totalling 120,000 warrants carry the right to subscribe for newly issued shares in 2cureX AB in the period from October 1, 2023 up to an including December, 31, 2023. Each subscription warrant entitles the holder to subscribe for 1 share, at a subscription price equal to 110 percent of the volume weighted average price at Nasdaq First North Growth Market during a period of ten trading days following the extra general meeting on November 5, 2020. Upon full exercise of the issued warrants, the share capital would increase by 12,000 SEK. The warrants will be subject to the usual conversion terms in connection with new share issues etc.

The Annual General Meeting on May 27, 2021 resolved to establish a Series 2021/24 warrant program for the Group's CEO. The warrants, totalling 700 000 warrants, carry the right to subscribe for newly issued shares in 2cureX AB in the period April 1, 2022 to 30 June 2022 (233 333 warrants), in the period April 1, 2023 to June 30, 2023 233 333 warrants) and in the period April 1, 2024 to June 30, 2024 (233 334 warrants), respectively.

The Group's result for Q1 2022 has been impacted by costs in the amount of 367 KSEK (399 KSEK) in the form of personnel costs.

POLICIES FOR THE PREPARATION OF THE INTERIM FINANCIAL REPORT
2cureX AB applies the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3) in the preparation of its financial reports.

AUDITORS' REVIEW
This interim report has not been reviewed by the Company's auditors.

FINANCIAL CALENDAR

The Company prepares and publishes a financial report at the end of each quarter. Upcoming reports are planned to be released as follows:

- **Annual General Meeting** **24/5-2022**
- **Interim Report Q2, 2022** **25/8-2022**
- **Interim Report Q3, 2022** **24/11-2022**
- **Interim Report Q4, 2022** **23/2-2023**

DELIVERY OF INTERIM REPORT

Landskrona, May 24, 2022 2cureX AB

BOARD OF DIRECTORS

Povl-André Bendz
Chairman of the Board

Jørgen Drejer
Member of the Board

Camilla Huse Bondesson
Member of the Board

Michael Lutz
Member of the Board

Ole Thastrup
Member of the Board and CSO

Nils Brünner
Member of the Board

Fernando Andreu
CEO

CERTIFIED ADVISER
Redeye AB
Phone: +46 8 121 576 90
E-mail: certifiedadviser@redeye.se

FINANCIAL OVERVIEW

FINANCIAL OVERVIEW THE GROUP

SUMMARY OF INCOME STATEMENT –THE GROUP (KSEK)	**Q1 2022** *1/1-31/3*	**Q1 2021** *1/1-31/3*	**2021** *1/1-31/12*
Operating income			
Net sales	0	0	0
Other operating income	434	3 850	7 391
Total operating income	**434**	**3 850**	**7 391**
Operating expenses			
Other external expenses	-3 300	-2 510	-11 863
Personnel costs	-5 147	-3 863	-17 976
Depreciation of tangible fixed assets	-74	-95	-353
Total operating expenses	**-8 521**	**-6 468**	**-30 192**
Operating profit	**-8 087**	**-2 618**	**-22 801**
Financial posts	190	396	322
Profit before tax	**-7 897**	**-2 222**	**-22 479**
Tax [1]	0	387	3 542
The result of the period	**-7 897**	**-1 835**	**-18 937**
Earnings per share (SEK)	-0,45	-0,12	-1,15
Average number of shares	17 513 876	14 856 600	16 418 767
No. of shares at the end of the period	17 602 916	14 856 600	17 475 716

[1] *This post refers to tax relief in subsidiaries regarding R&D work.*

SUMMARY OF BALANCE SHEET – THE GROUP (KSEK)	**Q1 2022** *1/1-31/3*	**Q1 2021** *1/1-31/3*	**2021** *1/1-31/12*
Assets			
Fixed assets			
Tangible fixed assets	626	947	691
Total fixed assets	**626**	**947**	**691**
Current assets			
Receivables	5 659	5 980	5 527
Cash and bank balances	63 348	53 991	72 942
Total current assets	**69 007**	**59 971**	**78 469**
Total assets	**69 633**	**60 918**	**79 160**
Equity and liabilities			
Equity			
Share capital	1 760	1 486	1 748
Ongoing share issue	0	0	1 068
Other contributed capital	107 664	75 388	106 608
Other equity	-34 781	-17 900	-16 143
The result of the period	-7 897	-1 835	-18 937
Total equity	**66 746**	**57 139**	**74 344**
Current liabilities			
Short-term liabilities [2)]	2 887	3 779	4 816
Total short-term liabilities	**2 887**	**3 779**	**4 816**
Total equity and liabilities	**69 633**	**60 918**	**79 160**

SUMMARY OF CASH FLOW – THE GROUP (KSEK)	**Q1 2022** *1/1-31/3*	**Q1 2021** *1/1-31/3*	**2021** *1/1-31/12*
Cash flow from operating activities	-9 710	-4 426	-18 426
Cash flow from investment activities	0	-27	-32
Cash flow from financing activities	0	0	32 550
Cash flow for the period	**-9 710**	**-4 955**	**14 092**
Cash and cash equivalents at the beginning of the period	72 942	58 577	58 577
Exchange rate difference in cash and cash equivalents	116	369	273
Cash and cash equivalents at the end of the period	**63 348**	**53 991**	**72 942**

CHANGE OF EQUITY – THE GROUP

1/1-2021 – 31/12-2021

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2021)	**1 486**	**0**	**75 388**	**-10 690**	**-7 320**	**58 864**
Outline of previous year's results				-7 320	7 320	0
Rights issue				2 027		2 027
Issue cost			-1 968			-1 968
Issue of shares	262		33 188			33 450
Ongoing share issue		1 068				1 068
Translation difference				-160		-160
The result of the period					-18 937	-18 937
At the end of the period (31/12-2021)	**1 748**	**1 068**	**106 608**	**-16 143**	**-18 937**	**74 344**

1/1-2022 – 31/3-2022

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2022)	**1 748**	**1 068**	**106 608**	**-16 143**	**-18 937**	**74 344**
Outline of previous year's results				-18 937	18 937	0
Registration of share issue	12	-1 068	1 056			0
Issue of warrants				388		388
Translation difference				-89		-89
The result of the period					-7 897	-7 897
At the end of the period (31/3-2022)	**1 760**	**0**	**107 664**	**-34 781**	**-7 897**	**66 746**

FINANCIAL OVERVIEW PARENT COMPANY

SUMMARY OF INCOME STATEMENT – PARENT COMPANY (KSEK)	**Q1 2022** *1/1-31/3*	**Q1 2021** *1/1-31/3*	**2021** *1/1-31/12*
Operating income			
Net sales	0	0	0
Total operating income	**0**	**0**	**0**
Operating expenses			
Other external expenses	-354	-301	-1 898
Staff costs	-304	-261	-839
Total operating expenses	**-658**	**-562**	**-2 737**
Operating profit	**-658**	**-562**	**-2 737**
Financial posts	-108	68	-1 072
Profit before tax	**-766**	**-494**	**-3 809**
Tax	0	0	0
The result of the period	**-766**	**-494**	**-3 809**

SUMMARY OF BALANCE SHEET – PARENT COMPANY (KSEK)	**Q1 2022** *1/1-31/3*	**Q1 2021** *1/1-31/3*	**2021** *1/1-31/12*
Assets			
Fixed assets			
Financial assets	34 555	28 550	29 275
Total fixed assets	**34 555**	**28 550**	**29 275**
Current assets			
Receivables	412	353	552
Cash and bank balances	61 510	37 034	67 176
Total current assets	**61 922**	**37 387**	**67 728**
Total assets	**96 477**	**65 937**	**97 003**
Equity and liabilities			
Equity			
Share capital	1 760	1 486	1 748
Premium fund	111 864	79 588	110 808
Ongoing share issue	0	0	1 068
Balanced result	-16 586	-15 028	-13 165
The result of the period	-766	-494	-3 809
Total equity	**96 272**	**65 552**	**96 650**
Current liabilities			
Current liabilities	205	385	353
Total short-term liabilities	**205**	**385**	**353**
Total equity and liabilities	**96 477**	**65 937**	**97 003**

SUMMARY OF CASH FLOW – PARENT COMPANY (KSEK)	**Q1 2022** *1/1-31/3*	**Q1 2021** *1/1-31/3*	**2021** *1/1-31/12*
Cash flow from operating activities	-666	-927	-3 335
Cash flow from investment activities	-5 000		0
Cash flow from financing activities	0		32 550
Cash flow for the period	**-5 666**	**-927**	**29 215**
Cash and cash equivalents at the beginning of the period	67 176	37 961	37 961
Cash and cash equivalents at the end of the period	**61 510**	**37 034**	**67 176**

CHANGE OF EQUITY – PARENT COMPANY

1/1-2021 – 31/12-2021

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2021)	**1 486**	**0**	**79 588**	**-13 164**	**-2 028**	**65 882**
Outline of previous year's results				-2 028	2 028	0
Issue of warrants				2 027		2 027
Issue costs			-1 968			-1 968
Rights issue	262		33 188			33 450
Ongoing share issue		1 068				1 068
The result of the period					-3 809	-3 809
At the end of the period (31/12-2021)	**1 748**	**1 068**	**110 808**	**-13 165**	**-3 809**	**96 650**

1/1-2022 – 31/3-2022

(KSEK)	Share capital	Ongoing share issue	Other contributed capital	Other equity	Result of the period	Total
At the beginning of the period (1/1-2022)	**1 748**	**1 068**	**110 808**	**-13 165**	**-3 809**	**96 650**
Outline of previous year's results				-3 809	3 809	0
Registration of share issue	12	-1 068	1 056			0
Issue of warrants				388		388
The result of the period					-766	-766
At the end of the period (31/3-2022)	**1 760**	**0**	**111 864**	**-16 586**	**-766**	**96 272**

THE POWER OF PRECISION. FOR EVERY ONCOLOGIST. TODAY.

2CUREX AB (publ)

Corporate registration number: **559128-0077**

2CUREX A/S

Fruebjergvej 3 / DK-2100 Copenhagen / Denmark

Phone: +45 2211 5399 / E-mail: info@2curex.com